Company Overview and News

16
TPI Composites: Will Green Energy Make A Comeback?

5h seekingalpha
Despite recent headlines on wind power reliability and tax credits, the wind industry is still posting excellent long term growth metrics.
PTC GEC GE TPIC GNE

46
7 Tech Stocks Sporting Amazon-Like Growth

2018-09-13 investorplace - 1
There’s no doubt that we continue to be in a growth-fueled market. This hasn’t always been the case. In case you’ve forgotten, after the financial meltdown, it was dividend stocks that were the ‘new’ growth stocks. Everyone was scrambling for dividends, and not surprisingly, many stocks began to offer tantalizing dividends.
AMZN TPIC CTRL SNE ABMD SNEJF TNET

15
TPI Composites (TPIC) CEO Steve Lockard on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Good afternoon. And welcome to TPI Composites' Second Quarter 2018 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A.
TPIC GM

1
TPI Composites, Inc. to Participate at Upcoming Investor Conferences

2018-08-08 globenewswire
SCOTTSDALE, Ariz., Aug. 08, 2018 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (“TPI”) (Nasdaq: TPIC), the only independent manufacturer of composite wind blades with a global footprint, today announced that its management team will attend the following investor conferences:
TPIC

1
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-08-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
TPIC

1
TPIC / TPI Composites, Inc. 10-Q (Quarterly Report)

2018-08-08 sec.gov
tpic-10q_20180630.htm UNITED STATES
TPIC

1
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-07-09 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

1
TPI and Vestas Expand Relationship in Mexico

2018-07-09 globenewswire
SCOTTSDALE, Ariz., July 09, 2018 (GLOBE NEWSWIRE) -- TPI Composites, Inc., (TPI) (Nasdaq:TPIC), the only independent manufacturer of composite wind blades with a global footprint, announced today that Vestas Wind Systems A/S has exercised an option to add two more V136 blade manufacturing lines under an existing multiyear supply agreement. TPI will produce blades from six lines for Vestas at TPI’s new manufacturing hub in Matamoros, Mexico.
VWSYF TPIC VWDRY

28
7 Renewable Energy Stocks to Buy for Sunny Long-Term Returns | InvestorPlace

2018-06-27 investorplace - 2
The 2020 Olympic Summer Games are to be held in Tokyo, Japan. The organizers of the games are planning to power the events with 100% renewable energy, which is great news for renewable energy stocks.
BAMGF TAC TPIC NAV RNW REGI EVA BAMKF NEE BAM TERP TRSWF BEP

2
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-05-22 sec.gov - 2
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

52
Merit Medical Systems price target raised to $62 from $55 at SunTrust Robinson Humphrey

2018-05-18 marketwatch
Growth at a reasonable price or the GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
TOWR MMSI IBTX INPAP TPIC DEST APVO EW INDB PDCO IBCP IP BSX SBAC

 
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-05-17 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

 
TPIC / TPI Composites, Inc. FORM 8-K (Current Report)

2018-05-09 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

 
TPI and Vestas Expand Relationship in Mexico

2018-05-09 globenewswire
SCOTTSDALE, Ariz., May 09, 2018 (GLOBE NEWSWIRE) -- TPI Composites, Inc., (TPI) (Nasdaq:TPIC), the only independent manufacturer of composite wind blades with a global footprint, announced today that Vestas Wind Systems A/S has exercised an option for two additional blade manufacturing lines under an existing multiyear supply agreement. TPI will produce blades for Vestas’ 4 MW wind turbine platform at TPI’s new facility in Matamoros, Mexico.
VWSYF TPIC VWDRY

1
TPIC / TPI Composites, Inc. 8-K (Current Report)

2018-05-07 sec.gov - 1
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TPIC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TPIC / TPI Composites, Inc. on message board site Silicon Investor.

Netpicks Netpicks Netpicks
CUSIP: 87266J104